AMPX vs ATKR

AMPX exhibits weak deterministic health with a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite this, the stock is trading at a premium valuation (Forward P/E: 182.91, Price/Sales: 33.78) driven by extraordinary revenue growth (137.4% YoY) and strong earnings surprises (average +52.81% over last 4 quarters). Analyst consensus is strongly bullish with a 'strong_buy' rating and a $20.00 target, reflecting high growth expectations. Insider selling activity (8 transactions, $37.78M) introduces bearish sentiment, but the company's technical trend and recent price momentum suggest strong market confidence. The Graham Number and intrinsic value are unavailable, indicating no defensive margin of safety.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong Current Ratio and manageable Debt/Equity, the company is unprofitable on a net basis (Profit Margin: -0.53%, ROE: -1.03%) and facing sharp earnings contraction (YoY EPS Growth: -71.6%). Valuation appears stretched relative to peers with a Forward P/E of 12.23 while operating in a declining revenue environment (Revenue Growth YoY: -4.60%), and the lack of a Graham Number or Altman Z-Score limits confidence in intrinsic value and solvency safety. Although the dividend yield is modestly attractive at 1.80% with a sustainable payout ratio, weak earnings momentum, deteriorating profitability, and neutral insider activity suggest substantial downside risks.